Top Page
Anteris Technologies Global Corp.
(NASDAQ:AVR)
Anteris Technologies Global Corp. (AVR) vs. SPDR S&P 500 ETF (SPY)
Anteris Technologies Global Corp. Business Overview & Revenue Model
Anteris Technologies Global Corp. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.14M | 2.70M | 2.73M | 3.20M | 5.83M | 5.46M |
| Gross Profit | 1.45M | 1.27M | 876.80K | 298.38K | 1.91M | 3.36M |
| EBITDA | -84.73M | -76.86M | -45.54M | -29.14M | -15.50M | -14.05M |
| Net Income | -84.32M | -76.29M | -46.02M | -30.56M | -17.17M | -11.78M |
Balance Sheet | ||||||
| Total Assets | 19.07M | 80.70M | 30.53M | 15.99M | 21.43M | 9.75M |
| Cash, Cash Equivalents and Short-Term Investments | 9.12M | 70.46M | 21.03M | 9.29M | 15.46M | 3.36M |
| Total Debt | 2.35M | 1.40M | 1.60M | 952.79K | 4.14M | 2.92M |
| Total Liabilities | 15.71M | 18.02M | 11.63M | 6.95M | 10.91M | 7.90M |
| Stockholders Equity | 3.70M | 62.76M | 19.30M | 9.03M | 10.52M | 1.86M |
Cash Flow | ||||||
| Free Cash Flow | -79.43M | -63.51M | -37.03M | -31.08M | -15.02M | -11.30M |
| Operating Cash Flow | -77.51M | -61.24M | -34.63M | -29.42M | -14.44M | -11.08M |
| Investing Cash Flow | -562.57K | -2.28M | -2.58M | -992.57K | -886.07K | 5.99M |
| Financing Cash Flow | 76.57M | 112.83M | 49.34M | 23.27M | 27.42M | 1.46M |
Anteris Technologies Global Corp. Technical Analysis
Anteris Technologies Global Corp. Risk Analysis
Anteris Technologies Global Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $147.71M | -9.44 | -172.18% | ― | -1.32% | 55.62% | |
56 Neutral | $137.40M | -2.98 | -68.83% | ― | 16.63% | 10.43% | |
54 Neutral | $222.88M | -2.39 | -2462.70% | ― | -21.10% | -18.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $136.71M | -4.19 | -8.73% | ― | -31.29% | 65.68% | |
45 Neutral | $155.47M | -3.05 | -51.63% | ― | 7.90% | 19.92% | |
43 Neutral | $181.08M | -6.77 | -13.27% | ― | 4.68% | 55.37% |
Anteris Technologies Global Corp. Corporate Events
On December 13, 2025, Stephen Denaro resigned from the Board of Directors of Anteris Technologies Global Corp. and as a Class II director, effective immediately. His resignation was not due to any disagreements with the company, and he will continue to serve as the corporate secretary of Anteris Technologies Pty Ltd and as a member of the Board of Directors of the company’s Australian subsidiaries.
On December 3, 2025, Anteris Technologies Global Corp. conducted its Annual Meeting of stockholders, where several key proposals were voted on. These included the election of John Seaberg and Gregory Moss as directors, the appointment of KPMG as the independent auditor for 2025, and the approval of various grants of restricted stock units (RSUs) to key executives in connection with the company’s U.S. initial public offering and annual meeting. Additionally, amendments to the company’s Employee Incentive Plan and previous incentive plans were approved, reflecting strategic adjustments to enhance executive compensation and corporate governance.
On November 26, 2025, Anteris Technologies Global Corp. announced it would not renew its Supply and License Agreement with 4C Medical Technologies, Inc., which involved the supply of ADAPT® tissue for medical devices. This decision, effective June 1, 2026, will not incur early termination penalties and does not materially impact the company’s financial results.
On November 16, 2025, Anteris Technologies Global Corp. announced the 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli. The results, presented at the PCR London Valves conference, highlighted the valve’s favorable hemodynamic profile, with no valve-related mortality and a significant reduction in prosthesis-patient mismatch compared to existing commercial devices. These outcomes reinforce the potential of DurAVR® THV in advancing towards commercialization, with implications for improved patient outcomes in the treatment of aortic stenosis.
On November 3, 2025, Anteris Technologies Global Corp. announced that it received FDA approval to commence its PARADIGM Trial, a global pivotal study of the DurAVR® Transcatheter Heart Valve (THV). This trial, which has already begun in Denmark, marks a significant milestone for the company as it aims to provide robust clinical evidence to support a future Premarket Approval (PMA) submission in the United States and CE Mark approval in Europe. The trial will enroll approximately 1000 patients across the United States, Europe, and Canada to evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs).
On October 27, 2025, Anteris Technologies announced the successful enrollment and treatment of the first patients in the global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve (THV), aimed at patients with severe calcific aortic stenosis. This trial, which is expected to expand across the United States, Europe, and Canada, will provide comparative evidence on the safety and effectiveness of the DurAVR® THV against commercially available transcatheter aortic valve replacements, potentially impacting the company’s market positioning and treatment options for aortic stenosis patients.
On October 23, 2025, Anteris Technologies Global Corp. entered into agreements to sell shares of its common stock and CHESS Depositary Interests (CDIs), along with accompanying five-year warrants, to certain investors. The company successfully closed the offering on October 27, 2025, issuing 2,346,936 shares and warrants, and raising approximately US$11.5 million in gross proceeds.
On October 23, 2025, Anteris Technologies Global Corp. announced agreements to sell over 5 million shares and accompanying warrants, expected to generate approximately US$25 million in gross proceeds. The offerings, managed by Evolution Capital Pty Ltd, are set to close by the end of October 2025, with the funds likely enhancing Anteris’ market position and supporting its strategic initiatives in the TAVR market.
Anteris Technologies Global Corp. will hold its first Annual Meeting of Stockholders on December 3, 2025, with the record date for stockholders set for October 30, 2025. The company has outlined procedures for stockholder proposals to be included in the proxy materials, emphasizing compliance with SEC rules and Delaware law, with a submission deadline of October 25, 2025.
On October 15, 2025, Anteris Technologies Global Corp. announced it received its first European regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve global pivotal trial, known as the PARADIGM Trial, for patients with severe calcific aortic stenosis. This milestone positions Anteris to expand the trial across the United States, Europe, and Canada, with patient recruitment in Denmark expected to begin in the fourth quarter of 2025. The trial aims to assess the safety and effectiveness of the DurAVR® valve compared to commercial TAVR devices, potentially leading to multiple approvals and commercialization opportunities. The announcement marks a significant step in Anteris’s lifecycle, reflecting strong interest from clinicians and the potential to transform care for aortic stenosis patients.
On September 29, 2025, Anteris Technologies Global Corp. held a special meeting where stockholders approved the ASX Waiver Proposal, allowing the company to issue new securities without stockholder approval under certain conditions. Additionally, the company provided an update on its PARADIGM Trial, with patient enrollment now expected to commence in the fourth quarter of 2025 following additional information requests from the FDA, demonstrating the company’s ongoing commitment to advancing its heart valve technology globally.